Skip to content
Homepage
Author:
Oryzon Genomics, S.A.
Posted Date:
July 27, 2026
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
Oryzon Genomics, S.A.
July 27, 2026
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
Oryzon Genomics, S.A.
July 8, 2026
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
Oryzon Genomics, S.A.
July 1, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
Oryzon Genomics, S.A.
June 11, 2026
